Immunology · Inborn Errors of Immunity

Tailoring Your Care: Standard and Emerging Treatments for IEI

At a Glance

Treatment for Inborn Errors of Immunity (IEI) is highly customized to a patient's genetic mutation. Standard care includes Immunoglobulin Replacement Therapy (IVIG or SCIG) and prophylactic antimicrobials. Severe cases may be cured using stem cell transplants or emerging gene therapies.

Treating an Inborn Error of Immunity (IEI) is tailored to your specific genetic “blueprint.” The goal is to provide a shield against infections while managing any underlying inflammation or autoimmunity ^[1]^[2].

Critical Warning: Always consult your immunologist before receiving any live-attenuated vaccines (like MMR, rotavirus, or chickenpox), as these can be life-threatening for patients with certain IEIs, particularly T-cell defects ^[3].

Antibody Replacement: Choosing Your Shield

For those with antibody deficiencies (like CVID or XLA), the standard of care is Immunoglobulin Replacement Therapy (IgRT) ^[1]. You and your doctor will typically choose between two main methods:

Intravenous (IVIG): Infused into a vein in a hospital or clinic every 3 to 4 weeks. Many patients prefer IVIG because it only requires a once-a-month time commitment ^[4]. However, it can cause a “wear-off” effect toward the end of the cycle.
Subcutaneous (SCIG): Infused into the fatty tissue under the skin, usually done at home weekly. SCIG provides more stable, consistent antibody levels without the “wear-off” effect ^[4]^[5]. Many prefer it for the independence it offers ^[6]^[7].

Note on Logistics: IgRT is highly expensive. Your care team will need to navigate prior authorizations with your insurance and coordinate with specialty pharmacies. Expect some administrative hurdles as you begin therapy.

Prophylactic Medicines: The Safety Net

Many patients take low-dose, daily medications to prevent infections before they start (prophylaxis) ^[8]:

Antibiotics: Prevent recurrent pneumonia or sinus infections.
Antifungals: Critical for conditions like Chronic Granulomatous Disease (CGD) to prevent fungal lung infections ^[9].
Antivirals & Specialized Prophylaxis: For patients with T-cell or combined defects, daily antivirals (e.g., acyclovir) and Pneumocystis (PCP/PJP) pneumonia prophylaxis (e.g., Bactrim) are life-saving, standard-of-care protocols ^[9].

Curative Treatments: Rebuilding the System

For severe forms of IEI, doctors aim for a permanent cure ^[10].

Hematopoietic Stem Cell Transplantation (HSCT)

Commonly known as a bone marrow transplant, HSCT replaces the faulty immune system with healthy stem cells from a donor ^[11].

Timing: For classic infant SCID, the best outcomes (survival rates >90%) occur when performed before 3.5 months of age ^[12]^[13]. However, HSCT is also successfully performed in older patients and for other types of IEI ^[14].
Infection Status: It is critical that the patient is infection-free at the time of transplant, as active infections lower the success rate ^[13]^[15].

Gene Therapy: The Next Frontier

For patients lacking a well-matched donor, gene therapy involves taking your own stem cells, “fixing” the genetic error in a lab, and returning them to your body. While still maturing, this technology avoids the risks of donor rejection ^[16]^[17].

Precision Medicine: The “Dimmer Switch”

If your IEI is caused by an “overactive” pathway (a Gain-of-Function mutation), your doctor may prescribe targeted therapies. Drugs like JAK inhibitors act like a “dimmer switch,” specifically turning down the inflammation ^[18]^[19].

Treatment Strategy by Severity

If the defect is…	The primary goal is…	Common treatments include…
Antibody Gap	Prevent bacterial infections	IVIG/SCIG and prophylactic antibiotics ^[1].
Immune Dysregulation	Calm the overactive system	Targeted biologics or JAK inhibitors ^[18].
Total Immune Failure	Rebuild the whole system	HSCT or Gene Therapy ^[11]^[16].

Common questions in this guide

What is the difference between IVIG and SCIG for IEI?

Intravenous immunoglobulin (IVIG) is given in a clinic every few weeks, while subcutaneous immunoglobulin (SCIG) is injected under the skin at home weekly. SCIG provides more stable antibody levels without the wear-off effect some people experience at the end of an IVIG cycle.

Can I receive standard vaccines if I have an Inborn Error of Immunity?

You must always consult your immunologist before receiving any live-attenuated vaccines, such as MMR, rotavirus, or chickenpox. These live vaccines can be life-threatening for patients with certain types of IEI, especially those with T-cell defects.

What are prophylactic medicines used for in primary immunodeficiency?

Prophylactic medicines are daily, low-dose treatments taken to prevent infections before they start. These serve as a safety net and often include antibiotics, antifungals, or antivirals depending on your specific immune defect.

Is there a permanent cure for Inborn Errors of Immunity?

Severe forms of IEI can sometimes be permanently cured using a hematopoietic stem cell transplant (HSCT), which replaces the faulty immune system. Gene therapy is also emerging as a potential cure by correcting the genetic error in a patient's own stem cells.

Are there targeted therapies for my specific genetic defect?

Yes, if your IEI is caused by an overactive immune pathway, doctors may use targeted therapies like JAK inhibitors. These act like a dimmer switch to specifically reduce harmful inflammation caused by the genetic mutation.

Curated prompts to bring to your next appointment.

1.Is my (or my child's) specific subtype a candidate for Subcutaneous Immunoglobulin (SCIG) instead of Intravenous (IVIG)?
2.Are there any 'targeted' or 'mechanism-based' therapies (like JAK inhibitors) available for my specific genetic defect?
3.If we are considering Hematopoietic Stem Cell Transplantation (HSCT), what is our plan to ensure an 'infection-free' status before the procedure?
4.Should we be using daily prophylactic antibiotics, antivirals, or antifungals, and what side effects should we watch for?
5.Are there any active gene therapy clinical trials for my specific IEI subtype?

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References (19)

1
Inborn errors of immunity (primary immunodeficiencies).
Kim VHD, Upton JEM, Derfalvi B, et al.
Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology 2025; (20(Suppl 3)):76 doi:10.1186/s13223-024-00938-z.
PMID: 39780212
2
Inborn Errors of Immunity.
Baloh CH, Chong H
The Medical clinics of North America 2024; (108(4)):703-718 doi:10.1016/j.mcna.2023.08.006.
PMID: 38816112
3
Fatal viscerotropic and neurotropic disease after yellow fever vaccine: a rare manifestation leading to diagnosis of severe combined immunodeficiency in an infant.
Vieira LJT, Goebel GA, Barcelos Y, et al.
Revista do Instituto de Medicina Tropical de Sao Paulo 2024; (66()):e50 doi:10.1590/S1678-9946202466050.
PMID: 39194142
4
Bridging the Gap in Secondary Antibody Deficiencies: Current Evidence and Unmet Needs in Diagnosis and Management with Immunoglobulin Replacement.
Kan AKC, Chan BCY, Lau CS, Li PH
Clinical reviews in allergy & immunology 2025; (68(1)):106 doi:10.1007/s12016-025-09116-4.
PMID: 41351689
5
A Retrospective Study on the Efficacy of Subcutaneous Immunoglobulin as Compared to Intravenous Formulation in Patients with Chronic Lymphocytic Leukemia and Secondary Antibody Deficiency.
Visentin A, Molinari MC, Pravato S, et al.
Current oncology (Toronto, Ont.) 2022; (30(1)):274-283 doi:10.3390/curroncol30010022.
PMID: 36661671
6
Patient-reported outcomes with subcutaneous immunoglobulin in secondary immunodeficiency.
Cowan J, Na IK, Gladiator A, et al.
Frontiers in immunology 2025; (16()):1528414 doi:10.3389/fimmu.2025.1528414.
PMID: 40181959
7
Immunoglobulin replacement therapy in patients with primary and secondary immunodeficiencies: impact of infusion method on immunoglobulin-specific perceptions of quality of life and treatment satisfaction.
Mallick R, Hahn N, Scalchunes C
Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology 2025; (21(1)):2 doi:10.1186/s13223-024-00939-y.
PMID: 39773529
8
Overview of secondary immunodeficiency.
Herman KE, Tuttle KL
Allergy and asthma proceedings 2024; (45(5)):347-354 doi:10.2500/aap.2024.45.240063.
PMID: 39294908
9
Inborn errors of immunity and invasive fungal infections: presentation and management.
Paccoud O, Warris A, Puel A, Lanternier F
Current opinion in infectious diseases 2024; (37(6)):464-473 doi:10.1097/QCO.0000000000001062.
PMID: 39259685
10
Clinical, Immunological, and Molecular Findings in 57 Patients With Severe Combined Immunodeficiency (SCID) From India.
Aluri J, Desai M, Gupta M, et al.
Frontiers in immunology 2019; (10()):23 doi:10.3389/fimmu.2019.00023.
PMID: 30778343
11
Genetically-determined defects of T cell development.
Notarangelo LD
Allergy and asthma proceedings 2024; (45(5)):326-331 doi:10.2500/aap.2024.45.240028.
PMID: 39294907
12
SCID genotype and 6-month posttransplant CD4 count predict survival and immune recovery.
Haddad E, Logan BR, Griffith LM, et al.
Blood 2018; (132(17)):1737-1749 doi:10.1182/blood-2018-03-840702.
PMID: 30154114
13
Survival After Hematopoietic Stem Cell Transplantation in Severe Combined Immunodeficiency (SCID): A Worldwide Review of the Prognostic Variables.
Goebel GA, de Assis CS, Cunha LAO, et al.
Clinical reviews in allergy & immunology 2024; (66(2)):192-209 doi:10.1007/s12016-024-08993-5.
PMID: 38689103
14
Haploidentical hematopoietic stem cell transplantation using post-transplant cyclophosphamide in patients with inborn errors of immunity: Experience in a reference center in Colombia
Medina D, Castro JO, Castro DE, et al.
Biomedica : revista del Instituto Nacional de Salud 2024; (44(Sp. 2)):118-130 doi:10.7705/biomedica.7560.
PMID: 39836841
15
Perspectives in newborn screening for SCID in Japan. Case report: newborn screening identified X-linked severe combined immunodeficiency with a novel IL2RG variant.
Beppu S, Nishikawa T, Tomomasa D, et al.
Frontiers in immunology 2024; (15()):1478411 doi:10.3389/fimmu.2024.1478411.
PMID: 39635533
16
Immunodeficiency: Gene therapy for primary immune deficiency.
Afzal SY, MacDougall MS, McGhee SA
Allergy and asthma proceedings 2024; (45(5)):384-388 doi:10.2500/aap.2024.45.240054.
PMID: 39294901
17
Recent advances in primary immunodeficiency: from molecular diagnosis to treatment.
Bucciol G, Meyts I
F1000Research 2020; (9()) doi:10.12688/f1000research.21553.1.
PMID: 32226610
18
Inborn errors of immunity: A field without frontiers.
Bucciol G, Delafontaine S, Meyts I, Poli C
Immunological reviews 2024; (322(1)):15-27 doi:10.1111/imr.13297.
PMID: 38062988
19
Inborn Errors of Immunity With Immune Dysregulation: From Bench to Bedside.
Delmonte OM, Castagnoli R, Calzoni E, Notarangelo LD
Frontiers in pediatrics 2019; (7()):353 doi:10.3389/fped.2019.00353.
PMID: 31508401

This page provides educational information about treatments for Inborn Errors of Immunity. Always consult your immunologist before starting any therapy, modifying medication, or receiving vaccines, as specific treatments depend on your exact genetic diagnosis.

Get notified when new evidence is published on Primary immunodeficiency.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Guide Contents